[go: up one dir, main page]

TW200637836A - Cytotoxic agents comprising new taxanes - Google Patents

Cytotoxic agents comprising new taxanes

Info

Publication number
TW200637836A
TW200637836A TW094142849A TW94142849A TW200637836A TW 200637836 A TW200637836 A TW 200637836A TW 094142849 A TW094142849 A TW 094142849A TW 94142849 A TW94142849 A TW 94142849A TW 200637836 A TW200637836 A TW 200637836A
Authority
TW
Taiwan
Prior art keywords
cytotoxic agents
taxanes
therapeutic use
novel cytotoxic
new taxanes
Prior art date
Application number
TW094142849A
Other languages
English (en)
Inventor
Michael L Miller
Ravi V J Chari
Erkan Baloglu
Alain Commercon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200637836(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of TW200637836A publication Critical patent/TW200637836A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW094142849A 2004-12-07 2005-12-06 Cytotoxic agents comprising new taxanes TW200637836A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04292898A EP1669358A1 (en) 2004-12-07 2004-12-07 Cytotoxic agents comprising new taxanes

Publications (1)

Publication Number Publication Date
TW200637836A true TW200637836A (en) 2006-11-01

Family

ID=34931583

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094142849A TW200637836A (en) 2004-12-07 2005-12-06 Cytotoxic agents comprising new taxanes

Country Status (22)

Country Link
US (1) US7667054B2 (zh)
EP (2) EP1669358A1 (zh)
JP (1) JP2008523019A (zh)
KR (1) KR20070085781A (zh)
CN (1) CN101094857A (zh)
AR (1) AR054100A1 (zh)
AU (1) AU2005313444B2 (zh)
BR (1) BRPI0518869A2 (zh)
CA (1) CA2588587A1 (zh)
DO (1) DOP2005000248A (zh)
EA (1) EA012625B1 (zh)
IL (1) IL183404A0 (zh)
MA (1) MA29103B1 (zh)
MX (1) MX2007006765A (zh)
MY (1) MY144632A (zh)
NO (1) NO20073033L (zh)
NZ (1) NZ555406A (zh)
PE (2) PE20110001A1 (zh)
TW (1) TW200637836A (zh)
UY (1) UY29249A1 (zh)
WO (1) WO2006061258A2 (zh)
ZA (1) ZA200704790B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
ES2609094T3 (es) * 2007-01-25 2017-04-18 Dana-Farber Cancer Institute, Inc. Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
JP5618549B2 (ja) * 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
MX2010001757A (es) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
UY32913A (es) 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
CN101851231A (zh) * 2010-05-27 2010-10-06 东北林业大学 一种多西紫杉醇新衍生物的合成方法及其在制备抗肿瘤药物中的应用
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
ES2939836T3 (es) 2012-07-12 2023-04-27 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
FI3122757T3 (fi) 2014-02-28 2023-10-10 Hangzhou Dac Biotech Co Ltd Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
CN104693156A (zh) * 2014-10-22 2015-06-10 上海大学 9,10-二羟基-1-去氧紫杉醇类似物及其制备方法
EP4678240A2 (en) 2015-07-12 2026-01-14 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
MX2019005583A (es) 2016-11-14 2019-10-21 Hangzhou Dac Biotech Co Ltd Vinculantes de conjugacion, conjugados de molecula de union a celulas que contienen los vinculantes, metodos de creacion y usos de dichos conjugados con los vinculantes.
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EP1242401B1 (en) * 1999-11-24 2006-12-27 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
JP2005539009A (ja) * 2002-08-02 2005-12-22 イミュノジェン・インコーポレーテッド 新規の効力のあるタキサンを含む細胞毒性物質、および、それらの治療用途

Also Published As

Publication number Publication date
CA2588587A1 (en) 2006-06-15
UY29249A1 (es) 2006-06-30
EP1669358A1 (en) 2006-06-14
DOP2005000248A (es) 2007-02-15
MA29103B1 (fr) 2007-12-03
EA012625B1 (ru) 2009-10-30
ZA200704790B (en) 2008-08-27
EP1824858A2 (en) 2007-08-29
BRPI0518869A2 (pt) 2008-12-16
KR20070085781A (ko) 2007-08-27
US20060178427A1 (en) 2006-08-10
PE20110001A1 (es) 2011-01-21
NO20073033L (no) 2007-08-28
IL183404A0 (en) 2007-10-31
WO2006061258A3 (en) 2006-09-28
NZ555406A (en) 2011-02-25
CN101094857A (zh) 2007-12-26
EA200701251A1 (ru) 2007-12-28
AU2005313444B2 (en) 2011-11-10
WO2006061258A2 (en) 2006-06-15
MY144632A (en) 2011-10-14
JP2008523019A (ja) 2008-07-03
MX2007006765A (es) 2007-08-16
PE20061060A1 (es) 2006-11-14
US7667054B2 (en) 2010-02-23
AR054100A1 (es) 2007-06-06
AU2005313444A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
TW200637836A (en) Cytotoxic agents comprising new taxanes
MY157715A (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
TW200640893A (en) Cytotoxic agents comprising new C-2 modified taxanes
MX2007008790A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso.
MX2007010996A (es) Nuevas composiciones de liposomas.
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
TW200610756A (en) Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
GEP20125565B (en) Lactam compounds and their pharmaceutical use
GB0625648D0 (en) Compounds
JO2721B1 (en) Derivatives of artemisia plant and its preparations and therapeutic applications
TW200505875A (en) Novel compounds
GEP20094844B (en) 3-aminocyclopentane carboxamides as modulators of chemokine receptors
GEP20094843B (en) 3-aminocyclopentane carboxamides as modulators of chemokine receptors
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
MX2009010689A (es) Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales.
MX2007003216A (es) Derivados y medicamentos sustituidos del cromano y su uso en terapias.
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
MX2009001433A (es) Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.
MX2007006042A (es) Bengamidas que poseen un ciclo caprolactama sustituido, procedimiento de preparacion, composiciones que las contienen y utilizacion.
MX2007002917A (es) Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.
TW200640858A (en) Substituted pyrroles, compositions containing them, method of manufacture and use
TW200745133A (en) New compounds II
UA92604C2 (ru) Композиция стансопорфина с физиологической осмотической концентрацией и ее применение